Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

A Single Center Retrospective Evaluation of Daratumumab Infusion Related Reactions with Split-First Dose Day 1 and Day 2 Infusion

Ali McBride, PharmD,MS, Muhammad Usman, MD, Muhammad Jahanzeb Khalil, MD, Muhammad Junaid Tariq, MD, Muhammad Asad Fraz, MD, Awais Ijaz, MD, Malik Qistas Ahmad, MD MBBS, Ali Younas Khan, MD, Sharoon Samuel, MD, Insija Ilyas Selene, MBBS, James Camamo, Cara Chang, PharmD, Jemin Aby Jose, MD, Faiz Anwer, MD

Blood (2018) 132 (Supplement 1): 5667.

https://doi.org/10.1182/blood-2018-99-119736

Published: 2018

Journal Articles

Reduction in Intravenous Infusion Duration of Enzyme Replacement Therapy to Ten Minutes with Velaglucerase Alfa in Adult Patients with Type 1 Gaucher Disease

Ari Zimran, MD, Shoshana Revel-Vilk, MD, Deborah Elstein, PhD, Naama Arbel, Michal Becker-Cohen, MSc, Gaya Chicco, Jeff Szer, MB, BS, FRACP

Blood (2017) 130 (Supplement 1): 2101.

https://doi.org/10.1182/blood.V130.Suppl_1.2101.2101

Published: 2017

Journal Articles

Potential New Treatment Option for Iron Deficiency Anemia Patients with a History of Unsatisfactory Oral Iron Therapy- Results of a Phase III, Randomized, Open-Label, Active-Controlled Trial of Ferumoxytol.

David Hetzel, Audrone Urboniene, Kristine Bernard, William Strauss, M.D., F.A.C.C., Michael Cressman, Zhu Li, PhD, Lee F. Allen, MD, PhD

Blood (2012) 120 (21): 2099.

https://doi.org/10.1182/blood.V120.21.2099.2099

Published: 2012

Journal Articles

Report on the Safety of Velaglucerase Alfa Enzyme Replacement Therapy in Patients with Type 1 Gaucher Disease and the Transition From Clinic to Home Infusions During Treatment Protocol HGT-GCB-058

Gregory M Pastores, Barry E Rosenbloom, MD, Neal J Weinreb, Ozlem Goker-Alpan, Rebecca Mardach, Mark Lipson, Jennifer Ibrahim, Gabriel M Cohn, David Zahrieh, Pramod K Mistry

Blood (2011) 118 (21): 1101.

https://doi.org/10.1182/blood.V118.21.1101.1101

Published: 2011

Journal Articles

Preclinical Safety of Baxter's Recombinant Factor VIIa

Barbara Dietrich, PhD, Susan Kubik, PhD, Wilfried Auer, PhD, Birgit Reipert, PhD, Frank Horling, PhD, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD, Hans Peter Schwarz, MD, Eva-Maria Muchitsch, PhD

Blood (2010) 116 (21): 1417.

https://doi.org/10.1182/blood.V116.21.1417.1417

Published: 2010

Journal Articles

Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia

Yoshiyuki Kosaka, Hiroshi Yagasaki, Kimihiko Sano, Ryoji Kobayashi, Hiroshi Ayukawa, Takashi Kaneko, Hiromasa Yabe, Masahiro Tsuchida, Hideo Mugishima, Akira Ohara, Akira Morimoto, Yoshitoshi Otsuka, Shouichi Ohga, Fumio Bessho, Tatsutoshi Nakahata, Ichiro Tsukimoto, Seiji Kojima

Blood (2008) 111 (3): 1054–1059.

https://doi.org/10.1182/blood-2007-08-099168

Published: 2008

Includes: Supplemental data

Journal Articles

A Randomized Placebo Controlled Phase II Trial of Prevention of Severe Oral Mucositis Using Single Dose Velafermin in Patients Receiving Myeloablative Therapy and Autologous Hematopoietic Stem Cell Transplant (AHSCT).

Michael W. Schuster, MD, J. Mehta, MD, E.K. Waller, MD, R.M. Rifkin, MD, I. Micallef, MD, D. Hurd, MD, S. Parekh, MD, P. Hari, MD, B.S. Skikne, MD, T.C. Shea, MD, D.A. Frei-Lahr, MD, R. Abonour, MD, C.O. Freytes, MD, L. Pineiro, MD, Y.C. Halvorsen, PhD, E.J. Anaissie, MD

Blood (2007) 110 (11): 615.

https://doi.org/10.1182/blood.V110.11.615.615

Published: 2007

Journal Articles

Hypersensitivity Reaction of Gemtuzumab Ozogamicin (Mylotarg™) Associated with Platelet Transfusion: Two Case Reports.

Amr Hanbali, MD, Ira Wollner, MD, Klodiana Neme, PharmD, Cynthia Ulreich, RN BSN OCN

Blood (2006) 108 (11): 4549.

https://doi.org/10.1182/blood.V108.11.4549.4549

Published: 2006

Journal Articles

Phenotypic and Genotypic Characteristics of Mastocytosis Differ According to the Age of Disease’s Onset.

Fanny Lanternier, MD, Annick Cohen-Akenine, PhD, Fabienne Palmerini, PhD, Frederic Feger, MD, Laurent Nasca, PhD, Stephane Barete, MD, David Guez, MD, Philippe Casassus, MD, PhD, Christine Bodemer, MD, PhD, Michel Arock, MD, PhD, Patrice Dubreuil, MD, PhD, Olivier Hermine, MD, PhD, Olivier Lortholary, MD, PhD

Blood (2005) 106 (11): 3091.

https://doi.org/10.1182/blood.V106.11.3091.3091

Published: 2005

Journal Articles

Rituximab for the Treatment of Adults with ITP: A Systematic Review.

Donald M. Arnold, MD, Francesco Dentali, MD, Ralph M. Meyer, MD, Mark A. Crowther, MD, Chris Sigouin, MSc, John G. Kelton, MD

Blood (2005) 106 (11): 1241.

https://doi.org/10.1182/blood.V106.11.1241.1241

Published: 2005

Journal Articles

Myocardial Infarction Induced by Intravenous Iron Dextran Infusion in Absence of Coronary Artery Disease.

Manmeet S. Ahluwalia, MD, Sandeep Patel, MD, Hamed Daw, MD

Blood (2004) 104 (11): 3694.

https://doi.org/10.1182/blood.V104.11.3694.3694

Published: 2004

Journal Articles

Prospective Multicenter Trial Comparing Repeated Immunosuppressive Therapy (IST) with Stem Cell Transplantation (SCT) from an Alternative Donor as a Second-Line Treatment for Children with Acquired Aplastic Anemia (AA).

Yoshiyuki Kosaka, Ryoji Kobayashi, Hiroshi Ayukawa, Koji Kato, Takashi Kaneko, Hisato Kigasawa, Hiromasa Yabe, Masahiro Tsuchida, Hideo Mugishima, Akira Ohara, Akira Morimoto, Masuji Yamamoto, Shouichi Ohga, Fumio Bessho, Tatsutoshi Nakahata, Ichiro Tsukimoto, Seiji Kojima

Blood (2004) 104 (11): 2815.

https://doi.org/10.1182/blood.V104.11.2815.2815

Published: 2004

NARROW

A Single Center Retrospective Evaluation of Daratumumab Infusion Related Reactions with Split-First Dose Day 1 and Day 2 Infusion

Reduction in Intravenous Infusion Duration of Enzyme Replacement Therapy to Ten Minutes with Velaglucerase Alfa in Adult Patients with Type 1 Gaucher Disease

Potential New Treatment Option for Iron Deficiency Anemia Patients with a History of Unsatisfactory Oral Iron Therapy- Results of a Phase III, Randomized, Open-Label, Active-Controlled Trial of Ferumoxytol.

Report on the Safety of Velaglucerase Alfa Enzyme Replacement Therapy in Patients with Type 1 Gaucher Disease and the Transition From Clinic to Home Infusions During Treatment Protocol HGT-GCB-058

Preclinical Safety of Baxter's Recombinant Factor VIIa

Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia

A Randomized Placebo Controlled Phase II Trial of Prevention of Severe Oral Mucositis Using Single Dose Velafermin in Patients Receiving Myeloablative Therapy and Autologous Hematopoietic Stem Cell Transplant (AHSCT).

Hypersensitivity Reaction of Gemtuzumab Ozogamicin (Mylotarg™) Associated with Platelet Transfusion: Two Case Reports.

Phenotypic and Genotypic Characteristics of Mastocytosis Differ According to the Age of Disease’s Onset.

Rituximab for the Treatment of Adults with ITP: A Systematic Review.

Myocardial Infarction Induced by Intravenous Iron Dextran Infusion in Absence of Coronary Artery Disease.

Prospective Multicenter Trial Comparing Repeated Immunosuppressive Therapy (IST) with Stem Cell Transplantation (SCT) from an Alternative Donor as a Second-Line Treatment for Children with Acquired Aplastic Anemia (AA).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only